Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Early effects of triamcinolone on vascular endothelial growth factor and endostatin in human choroidal neovascularization Tatar O; Shinoda K; Kaiserling E; Pertile G; Eckardt C; Mohr A; Yoeruek E; Szurman P; Bartz-Schmidt KU; Grisanti SArch Ophthalmol 2008[Feb]; 126 (2): 193-9OBJECTIVE: To evaluate the early effects of triamcinolone acetonide as monotherapy or as an adjuvant to ocular verteporfin photodynamic therapy (PDT) on angiogenesis in human choroidal neovascularization (CNV) secondary to age-related macular degeneration. METHODS: Retrospective review of an interventional series of 55 patients who underwent CNV extraction. Eleven patients were treated with intravitreal triamcinolone acetonide (4 mg) monotherapy (triamcinolone-treated CNV group [n = 5]) or with PDT-triamcinolone combination therapy (PDT-triamcinolone-treated CNV group [n = 6]) 3 to 9 days before surgery. Forty patients who underwent CNV extraction without previous therapy (control CNV group) and 4 patients who underwent CNV extraction 3 days after PDT (PDT CNV group) served as control subjects. The CNV samples were stained for CD34, endostatin, cytokeratin 18, and vascular endothelial growth factor (VEGF). RESULTS: Vascular endothelial growth factor expression was stronger in the PDT CNV samples (P < .001), triamcinolone CNV samples (P = .01), and PDT-triamcinolone CNV samples (P = .007) compared with the control CNV samples. There were no statistically significant differences in VEGF expression among the PDT CNV samples, triamcinolone CNV samples, and PDT-triamcinolone CNV samples. Endostatin expression was weaker in the PDT CNV samples than in the control CNV samples (P = .008). Endostatin expression was stronger in the triamcinolone CNV samples and the PDT-triamcinolone CNV samples compared with the control CNV samples (P = .001 and P < .001, respectively) and the PDT CNV samples (P < .001 for both). CONCLUSION: To some extent, triamcinolone monotherapy seems to exert its angiogenesis inhibitory effects on CNV by enhancing endostatin expression rather than by suppressing VEGF expression.|Aged[MESH]|Aged, 80 and over[MESH]|Anti-Inflammatory Agents/*therapeutic use[MESH]|Antigens, CD34/metabolism[MESH]|Choroidal Neovascularization/*drug therapy/etiology/metabolism[MESH]|Drug Therapy, Combination[MESH]|Endostatins/*metabolism[MESH]|Female[MESH]|Humans[MESH]|Immunoenzyme Techniques[MESH]|Keratin-18/metabolism[MESH]|Macular Degeneration/complications[MESH]|Male[MESH]|Middle Aged[MESH]|Photochemotherapy[MESH]|Photosensitizing Agents/therapeutic use[MESH]|Porphyrins/therapeutic use[MESH]|Retrospective Studies[MESH]|Triamcinolone Acetonide/*therapeutic use[MESH]|Vascular Endothelial Growth Factor A/*metabolism[MESH]|Verteporfin[MESH] |